N. Engl. J. Med.
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Abstract
Background
There is no established standard chemotherapy for patients with locally advanced or metastatic biliary tract cancer. We initially conducted a randomized, phase 2 study involving 86 patients to compare cisplatin plus gemcitabine with gemcitabine alone. After we found an improvement in progression-free survival, the trial was extended to the phase 3 trial reported here.
Methods
We randomly assigned 410 patients with locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer to receive either cisplatin (25 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter on days 1 and 8, every 3 weeks for eight cycles) or gemcitabine alone (1000 mg per square meter on days 1, 8, and 15, every 4 weeks for six cycles) for up to 24 weeks. The primary end point was overall survival.
Results
After a median follow-up of 8.2 months and 327 deaths, the median overall survival was 11.7 months among the 204 patients in the cisplatin-gemcitabine group and 8.1 months among the 206 patients in the gemcitabine group (hazard ratio, 0.64; 95% confidence interval, 0.52 to 0.80; P<0.001). The median progression-free survival was 8.0 months in the cisplatin-gemcitabine group and 5.0 months in the gemcitabine-only group (P<0.001). In addition, the rate of tumor control among patients in the cisplatin-gemcitabine group was significantly increased (81.4% vs. 71.8%, P=0.049). Adverse events were similar in the two groups, with the exception of more neutropenia in the cisplatin-gemcitabine group; the number of neutropenia-associated infections was similar in the two groups.
Conclusions
As compared with gemcitabine alone, cisplatin plus gemcitabine was associated with a significant survival advantage without the addition of substantial toxicity. Cisplatin plus gemcitabine is an appropriate option for the treatment of patients with advanced biliary cancer. (ClinicalTrials.gov number, NCT00262769.)
Related Questions
How do you sequence hypofractionated radiation and systemic therapy for patients with unresectable cholangiocarcinoma?
I have generally cared for patients analogously to that done in the initial NRG GI001 or ABC07 trial designs with the use of initial systemic therapy for 3-6 months followed by consolidative RT targeting a BED > 80.5, assuming a/b ratio of 10 Gy. Tao et al., PMID 26503201 In my practice, it’s most c...
What are best practices for oncologists during the national platinum shortage?
In breast cancer, we are prioritizing patients with curable disease in which platinum agents are a critical part of the regimen or have actually shown a clear advantage (the only example of this is shown below in bold).Use an alternative to a carboplatin-based regimen whenever possible. If no altern...
What is your approach to patients with unresectable, node-negative perihilar cholangiocarcinoma who have undergone biliary stenting and have no evidence of distant disease?
For perihilar cholangiocarcinoma that has been deemed unresectable by hepatobiliary surgeons, a good consideration is to have the patient evaluated for liver transplantation. The Mayo Clinic protocol allows tumor mass of <3cm, no nodal disease, and vascular involvement is allowed. Depending on the f...
How would you treat metastatic squamous cell carcinoma of the gall bladder?
Pure squamous cell carcinoma (SCC) of the gallbladder is an extremely rare entity, approximately 1-3% of all gallbladder cases (85-95% are adenocarcinoma). There have been some case reports and the few retrospective studies available, comparing outcomes between adenocarcinoma and SCC were mixed (Roa...
How do you treat metastatic adenocarcinoma of the ampulla of Vater?
True adenocarcinoma of the ampulla of Vater is an extremely rare cancer of the GI tract (<5 pts per million). Consequently, data is mostly derived from retrospective studies or large databases with few clinical trials available, especially with locally advanced and metastatic disease. I personally h...
For unresectable/metastatic cholangiocarcinoma, would you continue gemcitabine/cisplatin beyond 24 weeks if the patient continues to have a response to therapy?
I frequently continue beyond the 24 weeks used in the ABC-02 trial. Despite scarcity of good quality evidence, some form of maintenance chemotherapy is increasingly being used in advanced non-colorectal GI cancers such as biliary, pancreatic and esophagogastric cancers. More prolonged therapy has al...
What is your preferred second line of treatment after progression on cisplatin/gemcitabine for advanced or metastatic cholangiocarcinoma?
After progression on the front-line standard of gemcitabine and cisplatin (ABC-02, Valle et al. NEJM 2010), there is not an established second-line standard of care. There are several small prospective studies as well as some retrospective data that are indeed conflicting regarding the true efficacy...
What is the preferred palliative treatment regimen for elderly patients with advanced cholangiocarcinoma?
There is very limited data to provide a data driven approach to the management of elderly patients with advanced cholangiocarcinoma. In my clinical experience, gem/cis combinational chemotherapy as given in the ABC-02 trial is well tolerated for most older adults with preserved performance status an...
When do you consider local therapies (i.e. TACE) in patients with intrahepatic cholangiocarcinoma who do not tolerate or respond to chemothearpy or who are not surgical candidates?
The treatment of choice would be EBRT, ideally delivered to ablative doses or at least over 80 BED (Tao et al., PMID 26503201).For LC and OS benefits. This is an NCCN based recommendation based off of retrospective and single arm prospective (Hong et al., PMID 26668346) data. Two year LC 94% of IHCC...